Medicines labeled for the same conditions
Alternatives to repotrectinib
26 other medicines are given the same way (oral) and in the same FDA class as repotrectinib or labeled mainly for the same use (lung cancer); 17 are in its class, kinase inhibitors: erlotinib, afatinib, selpercatinib, crizotinib and 13 more; the others include 1 topoisomerase inhibitor (FDA labels read October 8, 2026).
Which medicines are labeled for the same conditions as repotrectinib?
The first 24 of the 26, the same class first. Lung cancer lists all 55 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.
| Medicine and FDA class | Shared indication | Generic labelers (oral) | Pharmacy cost | Boxed warning | Shortage |
|---|---|---|---|---|---|
| Repotrectinibkinase inhibitor | this medicine | none listed | n/a | No | No current entry |
| Erlotinibkinase inhibitor · same class | Lung cancer | 10 labelers | n/a | No | No current entry |
| Afatinibkinase inhibitor · same class | Lung cancer | 1 labeler | n/a | No | No current entry |
| Selpercatinibkinase inhibitor · same class | Lung cancer | none listed | n/a | No | No current entry |
| Crizotinibkinase inhibitor · same class | Lung cancer | none listed | n/a | No | No current entry |
| Gefitinibkinase inhibitor · same class | Lung cancer | 4 labelers | n/a | No | No current entry |
| Brigatinibkinase inhibitor · same class | Lung cancer | none listed | n/a | No | No current entry |
| Dabrafenibkinase inhibitor · same class | Lung cancer | none listed | n/a | No | No current entry |
| Lorlatinibkinase inhibitor · same class | Lung cancer | none listed | n/a | No | A presentation being discontinued |
| Trametinibkinase inhibitor · same class | Lung cancer | none listed | n/a | No | No current entry |
| Capmatinibkinase inhibitor · same class | Lung cancer | none listed | n/a | No | No current entry |
| Lazertinibkinase inhibitor · same class | Lung cancer | none listed | n/a | No | No current entry |
| Alectinibkinase inhibitor · same class | Lung cancer | none listed | n/a | No | No current entry |
| Ceritinibkinase inhibitor · same class | Lung cancer | none listed | n/a | No | No current entry |
| Pralsetinibkinase inhibitor · same class | Lung cancer | none listed | n/a | Yes | No current entry |
| Taletrectinib adipatekinase inhibitor · same class | Lung cancer | none listed | n/a | No | No current entry |
| Tepotinibkinase inhibitor · same class | Lung cancer | none listed | n/a | No | No current entry |
| Zongertinibkinase inhibitor · same class | Lung cancer | none listed | n/a | No | No current entry |
| Dacomitinib | Lung cancer | none listed | n/a | No | A presentation being discontinued |
| Entrectinib | Lung cancer | none listed | n/a | No | No current entry |
| Sotorasib | Lung cancer | none listed | n/a | No | No current entry |
| Ensartinib | Lung cancer | none listed | n/a | No | No current entry |
| Topotecantopoisomerase inhibitor | Lung cancer | none listed | n/a | Yes | No current entry |
| Zidesamtinib | Lung cancer | none listed | n/a | No | No current entry |
| Adagrasib | Lung cancer | none listed | n/a | No | No current entry |
Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Repotrectinib: the full record
- label, generics, price, shortages, recalls